Abstract 141P
Background
In antibody-mediated oncotherapy, IgG monoclonal antibodies have been the class of choice for the treatment of different cancers. However, tumour-antigen specific IgE antibodies are emerging as a new avenue for cancer therapy. This class of antibody have a high affinity for cognate Fcε receptors expressed on tumour-resident immune cells, such as macrophages and mast cells, and a lack of inhibitory Fc receptors, offering the chance to activate anti-tumour responses in tissues. Recently, a tolerable safety profile and anti-tumour efficacy of an IgE antibody recognizing the tumour-associated antigen, folate receptor α (FRα), has been shown in the first-in-class clinical trial of this agent.
Methods
We engineered a monoclonal IgE antibody, with human constant domains, recognising CSPG4 to target human melanoma. In vitro Fab-mediated antitumour effects, and mediated antibody-dependent cellular cytotoxicity (ADCC) against melanoma cells by immune effector cells were evaluated. CSPG4 antigen may be cleaved and released from the surface of tumour cells, and may bind to anti-CSPG4 antibodies, preventing them from engaging tumour cells and impairing their anti-tumour efficacy; or complexes of shed CSPG4 may cross-link anti-CSPG4 IgE engaged with basophils, which could potentiate degranulation and type I hypersensitivity. CSPG4 antigen shedding was measured in melanoma cell supernatant and in human sera. As an early evaluation of safety, we tested the propensity for CSPG4 IgE to induce RBL-SX38 degranulation in the presence of melanoma patient sera, and in unfractionated patient blood in basophil activation tests (BAT).
Results
CSPG4 IgE bound to melanoma tumours, induced Fab-mediated antitumour effects, and mediated ADCC against melanoma cells. We measured minimal shedding of the CSPG4 antigen in melanoma cell supernatants. Low levels of CSPG4 were detected in the circulation of melanoma patients and healthy subjects, with no significant difference in levels between the groups. CSPG4 IgE did not trigger RBL-SX38 degranulation and did not activate basophils in the BAT assay, suggesting lack of propensity to trigger anaphylaxis.
Conclusions
Our findings suggest that CSPG4 IgE may be an efficacious and safe immunotherapy for melanoma.
Legal entity responsible for the study
The authors.
Funding
Epsilogen Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display